Trending...
- "One World in a New World" Amplifies Voices of Transformation, Resilience, and Global Connection
- Boston: Mayor Michelle Wu Refiles Residential Tax Relief Legislation
- Boston Public Schools Launches New Website
CAMBRIDGE, Mass., Sept. 26, 2024 ~ Apnimed, Inc., a pharmaceutical company specializing in the development of oral therapies for sleep-related breathing diseases, has announced its participation in the 4th Annual Needham Private Biotech Company Virtual 1x1 Forum on October 8-9, 2024.
The company will be hosting virtual investor meetings on Tuesday, October 8th. This event will provide an opportunity for Apnimed to showcase its latest product, AD109, which has the potential to be the first pharmacological treatment to improve oxygenation during sleep by directly addressing the underlying neuromuscular cause of upper airway collapse in people with obstructive sleep apnea (OSA).
AD109 is a combination of aroxybutynin, a novel antimuscarinic, and atomoxetine, a selective noradrenaline reuptake inhibitor (NRI). This unique combination targets the root cause of OSA and is designed to be taken once nightly as an oral pill. By simplifying intervention and addressing the underlying neuromuscular dysfunction present in all OSA cases, AD109 may help more people benefit from effective and restorative sleep.
More on Boston Chron
Obstructive sleep apnea is a serious chronic sleep-related breathing disease that affects over 54 million people in the U.S. and 1 billion people worldwide. It is characterized by repeated collapses of the upper airway during sleep, leading to intermittent oxygen deprivation. This can have serious long-term health consequences such as high blood pressure, cardiovascular disease, and type 2 diabetes.
Despite its prevalence and potential health risks, OSA remains underdiagnosed and undertreated. Many individuals with OSA either refuse or underutilize treatment options due to their complexity or invasiveness. Currently available treatments also do not address the underlying neuromuscular dysfunction present in all cases of OSA.
Apnimed aims to change this by providing novel oral therapies that simplify intervention and improve oxygenation for people living with OSA and other sleep-related breathing diseases. The company is also working on a joint venture with Shionogi & Co., Ltd, called Shionogi Apnimed Sleep Science (SASS), to expand its reach to other sleep-related breathing diseases.
Based in Cambridge, Massachusetts, Apnimed is dedicated to revolutionizing the treatment landscape for sleep-related breathing diseases. Through their innovative approach, they hope to elevate the health and expectations of everyone in the sleep-related breathing disease community.
For more information about Apnimed and their products, visit their website at apnimed.com or follow them on social media platforms such as X and LinkedIn.
Media Contact:
Brian Ritchie
Investor Contact:
The company will be hosting virtual investor meetings on Tuesday, October 8th. This event will provide an opportunity for Apnimed to showcase its latest product, AD109, which has the potential to be the first pharmacological treatment to improve oxygenation during sleep by directly addressing the underlying neuromuscular cause of upper airway collapse in people with obstructive sleep apnea (OSA).
AD109 is a combination of aroxybutynin, a novel antimuscarinic, and atomoxetine, a selective noradrenaline reuptake inhibitor (NRI). This unique combination targets the root cause of OSA and is designed to be taken once nightly as an oral pill. By simplifying intervention and addressing the underlying neuromuscular dysfunction present in all OSA cases, AD109 may help more people benefit from effective and restorative sleep.
More on Boston Chron
- Get to know Dr. Raphael E. Cuomo, PhD, Professor and Scientist at the University of California, San Diego
- Ohio Medicare (Plan Brian C. Moore), has once again been distinguished as Ohio's Top-Ranked and Number-One-Rated "Best Choice" Medicare Expert!
- Honoring Dr. King: A Commitment to Justice and Equity in Boston
- Boston: A Step Toward Safer Streets for All
- Vital Village Networks Selects Leaders for 2025 Community Food Systems Fellowship
Obstructive sleep apnea is a serious chronic sleep-related breathing disease that affects over 54 million people in the U.S. and 1 billion people worldwide. It is characterized by repeated collapses of the upper airway during sleep, leading to intermittent oxygen deprivation. This can have serious long-term health consequences such as high blood pressure, cardiovascular disease, and type 2 diabetes.
Despite its prevalence and potential health risks, OSA remains underdiagnosed and undertreated. Many individuals with OSA either refuse or underutilize treatment options due to their complexity or invasiveness. Currently available treatments also do not address the underlying neuromuscular dysfunction present in all cases of OSA.
Apnimed aims to change this by providing novel oral therapies that simplify intervention and improve oxygenation for people living with OSA and other sleep-related breathing diseases. The company is also working on a joint venture with Shionogi & Co., Ltd, called Shionogi Apnimed Sleep Science (SASS), to expand its reach to other sleep-related breathing diseases.
Based in Cambridge, Massachusetts, Apnimed is dedicated to revolutionizing the treatment landscape for sleep-related breathing diseases. Through their innovative approach, they hope to elevate the health and expectations of everyone in the sleep-related breathing disease community.
For more information about Apnimed and their products, visit their website at apnimed.com or follow them on social media platforms such as X and LinkedIn.
Media Contact:
Brian Ritchie
Investor Contact:
Filed Under: Business
0 Comments
Latest on Boston Chron
- Matthew Cossolotto's The Joy of Public Speaking – Helping Readers Move from Stage Fright to Stage Delight – Wins 2024 Maincrest Media Book Award
- Lady Bird Laser Spa: Empowering Beauty with Advanced Skin Treatments and Exceptional Service
- Profitable Exciting New Entry Into Emerging Global MOBA Digital Game Arena, Plus New Strategic Partnership with The9 Limited: NIP Group; Stock: NIPG
- City of Boston Awarded a Grant from the EPA For $35 Million For 125 New Electric School Buses
- A Historic Night Awaits: RNHA Celebrating the Power of the Latino Vote at Inauguration 2025
- Namebadges.com Expands Shipping Services to Mexico and Canada
- Keells Leverages Cyntexa and Salesforce to Redefine Customer Loyalty with Digital Innovation
- Peak Physical Therapy & Sports Performance Returns Winter Sports Program
- JH Technologies Partners with Xavis to Deliver Advanced X-Ray Inspection to North America
- PhaseZero Releases CxCommerce™ 7.0 with Proven Scale for the Largest Enterprises and Affordability for Small Businesses
- Century Fasteners Corp. Mourns the Loss of Colleague and Friend, Mark James
- COLORICH PACKAGING Will Participate in the COSME Week 2025 TOKYO and Cosmoprof Worldwide Bologna 2025 Exhibition
- IntellaTriage Launches New Patient Engagement Service
- Momentum Stock Trading: AI-Driven by Tickeron
- IntellaTriage Launches New Patient Engagement Service
- Cascadia Global Security Launches Cascadia Off-Duty
- CathVision to Showcase Innovations at AF Symposium, Present New Science
- Anti-Racism Song from Neal Fox Drops in Time for Martin Luther King Day
- Genpak Expands Foodservice Packaging to Include Durable, Polypropylene Bowls
- DayPass Expands to 50 New Destinations in 2024, Bringing Luxury Day Experiences to Travelers and Locals